Grufity logoGrufity logo
StocksFundsSearch Filings

Amyris Inc Stock Research

AMRS

0.82USD+0.07(+9.31%)Delayedas of 31 May 2023, 02:08 pm

Market Summary

USD0.82+0.07
Delayedas of 31 May 2023, 02:08 pm
9.31%

AMRS Stock Price

AMRS RSI Chart

AMRS Valuation

Market Cap

277.1M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

1.03

EV/EBITDA

-0.44

Price/Free Cashflow

-0.6

AMRS Price/Sales (Trailing)

AMRS Profitability

EBT Margin

-135.65%

Return on Equity

79.72%

Return on Assets

-45.2%

Free Cashflow Yield

-167.28%

AMRS Fundamentals

AMRS Revenue

Revenue (TTM)

268.2M

Revenue Y/Y

-2.82%

Revenue Q/Q

-26.01%

AMRS Earnings

Earnings (TTM)

-528.5M

Earnings Y/Y

-495.82%

Earnings Q/Q

7.19%

Price Action

52 Week Range

0.554.86
(Low)(High)

Last 7 days

1.0%

Last 30 days

-8.0%

Last 90 days

-36.8%

Trailing 12 Months

-71.8%

AMRS Financial Health

Current Ratio

0.88

AMRS Investor Care

Shares Dilution (1Y)

19.30%

Diluted EPS (TTM)

-1.92

Peers (Alternatives to Amyris)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
28.2B
47.5B
-8.34% -19.49%
9.28
0.59
-5.39% -48.13%
26.8B
17.7B
-4.21% 4.38%
24.98
1.52
2.87% 18.13%
19.9B
12.2B
-19.34% -40.77%
-10.7
1.63
-1.42% -768.10%
15.1B
15.1B
-4.69% -17.30%
6.74
0.96
12.00% -25.52%
10.3B
7.2B
-2.77% -11.41%
19.52
1.42
11.69% 17.31%
MID-CAP
6.4B
8.8B
-11.23% -25.87%
5.85
0.73
-7.34% -24.77%
5.3B
5.0B
-5.10% 7.77%
26.11
1.1
10.33% -27.28%
3.8B
2.8B
-1.18% 17.82%
11.96
1.36
14.40% 76.05%
3.2B
1.5B
-2.01% -16.73%
22.49
2.2
5.41% 10.73%
2.4B
-
1.27% 44.25%
215.39
2.37
- -
SMALL-CAP
809.2M
1.5B
-4.59% -19.92%
10.8
0.56
17.52% -46.24%
393.9M
427.9M
20.00% 23.63%
8.09
0.92
27.12% 91.20%
277.1M
268.2M
-8.05% -71.84%
-0.52
1.03
20.46% -95.04%

Financials for Amyris

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue-0.6%268,221,000269,847,000258,821,000235,558,000222,667,000
  S&GA Expenses-2.2%482,583,000493,629,000453,126,000399,052,000326,805,000
  R&D Expenses0.4%110,622,000110,215,000105,958,000101,002,00097,315,000
Costs and Expenses7.1%898,173,000838,830,000803,838,000719,242,000617,799,000
EBITDA-71.1%-313,100,000-182,997,000-62,647,000--
EBITDA Margin-55.7%-1.21-0.78-0.28--
Earnings Before Taxes-17.1%-630,997,000-538,625,000-351,102,000-218,064,000-92,187,000
EBT Margin-46.5%-1.36-0.93-0.44--
Interest Expenses31.2%32,453,00024,733,00027,604,00025,636,00025,055,000
Net Income-55.0%-528,510,000-340,868,000-212,417,000-87,023,000-
Net Income Margin-46.0%-1.32-0.90-0.39--
Free Cahsflow-12.6%-575,187,000-511,021,000-442,426,000--
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-17.6%680825754789898
  Current Assets-20.5%244306272310471
    Cash Equivalents-72.9%17.0064.0018.00100288
  Inventory-2.6%10911212999.0082.00
  Net PPE4.1%190182170151125
  Goodwill-64.6%50.001431271341.00
Liabilities2.7%1,3281,2931,1591,0331,024
  Current Liabilities21.6%471387309187266
    LT Debt, Current2.7%2.002.002.001.001.00
    LT Debt, Non Current0.1%676675674673672
Shareholder's Equity-35.9%-664-488---
  Retained Earnings-6.0%-3,073-2,900-2,730-2,568-2,458
  Additional Paid-In Capital0.4%2,4662,4562,3842,357-
Accumulated Depreciation2.3%99.0096.0095.00--
Shares Outstanding1.0%369365325321309
Minority Interest24.4%-9.76-12.91-13.10-6.60-3.52
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations11.9%-463-525-575-511-442
  Share Based Compensation-11.9%43.0049.0048.0045.0041.00
Cashflow From Investing34.3%-81.24-123-142-147-108
Cashflow From Financing16.3%269231626550698

Risks for AMRS

What is the probability of a big loss on AMRS?

100%


Probability that Amyris stock will be more than 20% underwater in next one year

94.2%


Probability that Amyris stock will be more than 30% underwater in next one year.

93.8%


Probability that Amyris stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amyris was unfortunately bought at previous high price.

Drawdowns

Returns for AMRS

Cumulative Returns on AMRS

-33.6%


10-Year Cumulative Returns

-29.4%


7-Year Cumulative Returns

-32%


5-Year Cumulative Returns

-41.4%


3-Year Cumulative Returns

What are the long-term rolling returns for AMRS?

FIve years rolling returns for Amyris.

Annualized Returns

Which funds bought or sold AMRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-7.07
-6,857
32,568
-%
2023-05-26
SHEETS SMITH WEALTH MANAGEMENT
sold off
-100
-82,836
-
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-8.44
-6,741
27,259
-%
2023-05-22
Arete Wealth Advisors, LLC
reduced
-7.92
-19,301,800
16,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-73.96
-142,000
43,000
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-22.46
-1,004,000
2,226,000
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-21.00
170
-%
2023-05-17
B. Riley Wealth Advisors, Inc.
unchanged
-
-12,631
101,048
-%
2023-05-16
CVI Holdings, LLC
sold off
-100
-27,791,800
-
-%
2023-05-16
IMA Wealth, Inc.
unchanged
-
-42.00
340
-%

1–10 of 27

Latest Funds Activity

Are funds buying AMRS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own AMRS
No. of Funds

Amyris News

Marketscreener.com
AMYRIS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to a Vote of Security Holders (form 8-K).
Marketscreener.com,
4 days ago
Seeking Alpha
Zacks Investment Research
Marketscreener.com

Schedule 13G FIlings of Amyris

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 24, 2023
foris ventures, llc
29.9%
120,177,411
SC 13D/A
Mar 17, 2023
foris ventures, llc
30.1%
119,877,165
SC 13D/A
Feb 14, 2023
cvi investments, inc.
4.9%
18,163,117
SC 13G/A
Feb 09, 2023
vanguard group inc
5.84%
21,211,189
SC 13G/A
Feb 07, 2023
farallon capital partners, l.p.
0.0%
64,221
SC 13G/A
Jan 09, 2023
foris ventures, llc
33.5%
119,710,362
SC 13D/A
Jan 04, 2023
cvi investments, inc.
5.5%
2e+07
SC 13G
Dec 16, 2022
dsm international b.v.
-
0
SC 13D/A
Sep 15, 2022
foris ventures, llc
28.0%
96,051,761
SC 13D/A
Sep 08, 2022
foris ventures, llc
27.5%
93,989,044
SC 13D/A

AMRS Fair Value

Show Fair-Value

Recent SEC filings of Amyris

View All Filings
Date Filed Form Type Document
May 26, 2023
8-K
Current Report
May 24, 2023
SC 13D/A
13D - Major Acquisition
May 10, 2023
10-Q
Quarterly Report
May 09, 2023
8-K
Current Report
Apr 24, 2023
EFFECT
EFFECT
Apr 24, 2023
EFFECT
EFFECT
Apr 24, 2023
8-K
Current Report
Apr 21, 2023
4
Insider Trading
Apr 21, 2023
4
Insider Trading
Apr 21, 2023
4
Insider Trading

Latest Insider Trading transactions for AMRS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-04-19
Panchadsaram Ryan
acquired
-
-
9,667
-
2023-04-19
MCCANN JAMES F
acquired
-
-
13,437
-
2023-04-19
Qi Lisa
acquired
-
-
10,537
-
2023-04-19
DOERR L JOHN
acquired
-
-
11,600
-
2023-04-05
ALVAREZ EDUARDO
sold
-284,305
1.2288
-231,368
chief operating officer
2023-04-04
ALVAREZ EDUARDO
acquired
-
-
492,000
chief operating officer
2023-01-20
Qi Lisa
acquired
-
-
7,532
-
2023-01-20
Panchadsaram Ryan
acquired
-
-
7,947
-
2023-01-20
MCCANN JAMES F
acquired
-
-
9,605
-
2023-01-20
DOERR L JOHN
acquired
-
-
8,292
-

1–10 of 50

John G. Melo
980
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

AMRS Income Statement

2023-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:  
Revenue$ 56,083$ 57,709
Cost and operating expenses:  
Cost of products sold51,08148,995
Research and development26,76526,358
Sales, general and administrative95,870106,916
Change in fair value of acquisition-related contingent consideration(28,503)0
Restructuring1,0130
Impairment95,3860
Total cost and operating expenses241,612182,269
Loss from operations(185,529)(124,560)
Other income (expense):  
Interest expense(12,983)(5,263)
Gain from change in fair value of derivative instruments1,2631,815
(Loss) gain from change in fair value of debt(4,854)20,796
Other expense, net(533)(3,052)
Total other (expense) income, net(17,107)14,296
Loss before income taxes and loss from investment in affiliate(202,636)(110,264)
Benefit from income taxes860820
Loss from investment in affiliate0(789)
Net loss(201,776)(110,233)
Loss attributable to noncontrolling interest8,4342,928
Net loss attributable to Amyris, Inc. common stockholders$ (193,342)$ (107,305)
Earnings Per Share [Abstract]  
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.53)$ (0.34)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, basic (in shares)365,603,738312,896,452
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.53)$ (0.37)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock, diluted (in shares)365,603,738323,711,682
Renewable Products  
Revenue:  
Revenue$ 40,224$ 43,465
Licenses and Royalties  
Revenue:  
Revenue9,4829,313
Collaborations, Grants and Other  
Revenue:  
Revenue$ 6,377$ 4,931

AMRS Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 11,245$ 64,437
Restricted cash7171
Accounts receivable, net of allowance of $997 and $99536,84245,775
Accounts receivable - related party, net of allowance of $0 and $010,8366,608
Contract assets3,872806
Contract assets - related party33,67936,638
Inventories109,021111,880
Prepaid expenses and other current assets38,09540,146
Total current assets243,661306,361
Property, plant and equipment, net189,645182,224
Restricted cash, noncurrent6,1356,090
Recoverable taxes from Brazilian government entities30,18929,472
Right-of-use assets under financing leases, net147152
Right-of-use assets under operating leases, net100,72197,216
Goodwill50,456142,575
Intangible assets, net45,06346,938
Other assets13,66213,904
Total assets679,679824,932
Current liabilities:  
Accounts payable200,067190,486
Accrued and other current liabilities81,06873,565
Financing lease liabilities1413
Operating lease liabilities2,4842,255
Contract liabilities3326
Debt, current portion1,9681,916
Related party debt, current portion185,160118,886
Total current liabilities470,794387,147
Long-term debt, net of current portion675,855674,891
Related party debt, net of current portion77,96297,350
Financing lease liabilities, net of current portion4448
Operating lease liabilities, net of current portion90,98686,195
Derivative liabilities4,1405,403
Acquisition-related contingent consideration2,24134,555
Other noncurrent liabilities5,7257,053
Total liabilities1,327,7471,292,642
Commitments and contingencies
Mezzanine equity:  
Contingently redeemable common stock05,000
Contingently redeemable noncontrolling interest26,05828,892
Stockholders’ (deficit) equity:  
Common stock - $0.0001 par value, 550,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 368,524,240 and 364,745,266 shares issued and outstanding as of March 31, 2023 and December 31, 20223736
Additional paid-in capital2,465,8022,455,567
Accumulated other comprehensive loss(56,682)(64,114)
Accumulated deficit(3,073,520)(2,880,178)
Total Amyris, Inc. stockholders’ (deficit) equity(664,363)(488,689)
Noncontrolling interest(9,763)(12,913)
Total stockholders' (deficit) equity(674,126)(501,602)
Total liabilities, mezzanine equity and stockholders' (deficit) equity$ 679,679$ 824,932